Johnson & Johnson (JNJ) reported Q4 FY 2018 earnings of $1.97 per share (versus $1.74 in Q4 FY 2017), beating analysts’ consensus estimate of $1.95.
The company’s quarterly revenues amounted to $20.394 bln (+1.0% y/y), generally in line with analysts’ consensus estimate of $20.267 bln.
The company also issued guidance for FY 2019, projecting EPS of $8.50-8.65 (versus analysts’ consensus estimate of $8.60) and revenues of $80.4-81.2 bln (versus analysts’ consensus estimate of $82.74 bln).
JNJ rose to $131.70 (+0.77%) in pre-market trading.